Introduction

CD44 is a widely distributed transmembrane glycoprotein expressed in different kinds of cells including lymphocytes, leukocytes, erythrocytes, epithelial cells, and fibroblasts[1-3] and functions as a cell adhesion molecule. Among its known ligands are hyaluronic acid, collagen, fibronectin, and others. CD44 usually has a molecular weight of 80 – 95 kDa; however, its many splicing variants that have higher molecular weights are also known.

In humans, CD44 is located on the short arm (p13) of chromosome 11[4]. Its gene sequence encodes the extracellular (exons 1 – 5 and 16), transmembrane (exon 17), and cytoplasmic (exons 18 – 20) domains. These domains make up the protein structure of CD44 standard (CD44s).

Variant isoforms of CD44 (CD44v) are generated by the alternative splicing of 10 variant exons (v1–v10) positioned between exons 5 and 16. Therefore, various isoforms can be found in CD44v, and they contain similar regions and variable functional domains[5,6].

CD44s and CD44v are members of the CD44 family, and recently, the relationship of this family with the progression and metastasis of malignant tumors has come under scrutiny. The relationship between CD44 and various malignant tumors such as colorectal[7,8], pulmonary[9-11], and gastric cancers[12,13] is being elucidated. In the field of head and neck cancer[14], an association of CD44 with prognosis has been reported[7-14]. Regardless of the type of cancer, there have been many reports revealing that CD44 positivity tends to be involved in metastasis and poor prognosis[15-18]. In particular, CD44v6 has come under intense scrutiny, and the expression of CD44v6 is associated with increased tumor progression and metastatic potential[19]. A report demonstrated that CD44v3 is present at higher levels in head and neck cancers than in normal tissues[20]; another report demonstrated that there is no difference between the expression of CD44s and CD44v6[21] and that the precise role of CD44 is not yet known. Furthermore, CD44 has been suggested to be a cancer stem cell marker in head and neck cancer[22]. A cancer stem cell is an undifferentiated clonal cell. It is pluripotent and has the ability to self-renew; it differentiates according to the en...

Abstract

Cancer stem cells are one of the most promising targets for cancer treatment. In head and neck cancer, CD44 has been regarded as a cancer stem cell marker. However, apart from the standard CD44 (CD44s), many other variants of CD44 exist, and their specific roles are still unknown. Radiation resistance is a known characteristic of cancer stem cells. Therefore, we irradiated five head and neck squamous cell carcinoma cell lines and investigated whether the expression patterns of CD44 variants changed. Common results showed that the number of CD44s-positive cells decreased and that of CD44 variant 9 (CD44v9)-positive cells increased. This suggested that CD44v9 is useful as a marker for cancer stem cells and may be a target for therapy.

Keywords: Cancer stem cell; Irradiation; CD44; HNSCC; CD44v9

Increased Expression of CD44v9, A Cancer Stem Cell Marker, in Head And Neck Squamous Cell Carcinoma Cells after Irradiation

Yohei Kawasaki1,2, Yasufumi Omori2*, Takechiyo Yamada1

1Department of Otorhinolaryngology and Head-and-Neck Surgery, Akita University Graduate School of Medicine, Akita, Japan
2Department of Molecular and Tumour Pathology, Akita University Graduate School of Medicine, Akita, Japan

*Corresponding author: Yasufumi Omori, Professor, Department of Molecular and Tumour Pathology, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543 Japan, Tel: +81 18-884-6059/ Fax: +81 18-836-2601; E-mail: yasu@med.akita-u.ac.jp

Received Date: August 02, 2017
Accepted Date: November 17, 2017
Published Date: November 20, 2017


DOI: 10.15436/2377-0902.17.1628

CrossMark

Copyrights: © 2017 Kawasaki, Y. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
environment, has metastatic potential, and is resistant to anticancer drugs and radiation.

Doubts have been raised about whether CD44 alone is suitable as a cancer stem cell marker; however, we believe that it is possible for one of the variants of CD44 to be used as a marker. Therefore, we irradiated five head and neck squamous cell carcinoma cell lines and established a resistant cell line. This approach should allow the natural enrichment of cancer stem cells. We then examined changes in the expression of CD44s, CD44v3, CD44v6, and CD44v9 and investigated CD44 variants that showed increased or decreased expression.

Material and Methods

Cell culture and irradiation

Human squamous cell carcinoma cell lines HO-1-u-1, Sa3, HSC2, HSC3, and HSC4 were purchased from RIKEN BRC (Ibaraki, Japan). For monolayer culture, cells were maintained in RPMI 1640 medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% FBS (Clontech Laboratories, Mountain View, CA, USA), 2 mM L-glutamine, 2.4 g/l NaHCO3, 100 U/ml penicillin, and 100 µg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA). The medium was replaced every other day. Under each culture condition, the cells were incubated at 37°C in a humidified atmosphere containing 5% CO2 in air.

Irradiation

Cells were sown in a 75 mm2 flask (Nunc, Roskilde, Denmark) and irradiated with 2 Gy (CP-160, Japan) every day after becoming sub confluent. Irradiation was continued to a total of 60 Gy. Then, the generated radio-resistant cells were maintained as mentioned above.

Flow cytometry

For CD44s, CD44v3, CD44v6, and CD44v9 analyses, trypsinized cell pellets were incubated with FITC-conjugated anti-human CD44s clone SFF-2 (eBioscience, San Diego, CA, USA), APC-conjugated anti-human CD44v3 clone 3G5 (R&D Systems, Inc., Minneapolis, MN, USA), APC-conjugated anti-human CD44v6 clone 2F10 (R&D Systems, Inc.), and APC-conjugated anti-human CD44v9 clone RV3 (Cosmo Bio Co., Ltd., Tokyo, Japan) at a dilution of 1:11 at 4°C for 30 min. After washing with PBS, cells were resuspended in 2 µg/ml PI, filtered through a 40-µm cell strainer and applied to a MoFlo Cell Sorter (Beckman Coulter, Fullerton, CA, USA). To determine the negative fraction, FITC-conjugated anti-mouse IgG1 antibody (eBioscience, San Diego, CA, USA), APC-conjugated anti-mouse IgG1 isotype antibody (R&D Systems, Inc.), APC-conjugated anti-mouse IgM isotype antibody (R&D Systems, Inc.), and APC-conjugated anti-rat IgG2a antibody (Abcam, Tokyo, Japan) were excited with an argon or a helium–neon laser.

Sphere formation assay

To avoid adhesion and subsequent maturation, cells were cultured in a serum-free semisolid medium. A total of 1 × 10^3 cells were seeded in 80 µl of serum-free RPMI1640 medium, the recipe of which was mentioned above, containing 0.33% agar on 100 µl of a solidified serum-free RPMI1640 basal layer and 0.5% agar in the wells of a 96-well plate. Fifty microliters of serum-free RPMI1640 was poured on the top of each well, and this top liquid layer was replaced every 3 days. The cells were incubated for 20 days under the same conditions as those for the monolayer culture. The number of formed spheres was counted.

Statistical analysis

Student’s t-test was performed for the estimation of statistical significance. p values are two-tailed. All experiments were independently repeated three times.

Result

CD44s expression reduced in all cell lines

The number of CD44s-positive cells was examined in the five cell lines after irradiation. There were differences in the number of CD44s-positive cells between the cell lines examined, but all cell lines showed a decrease in CD44s-positive cells after irradiation. It decreased from 3.35% to 0.81% in HO-1-u-1, from 48.5% to 0.17% in Sa3, from 75.4% to 55.7% in HSC2, from 19.1% to 5.1% in HSC3, and from 0.99% to 0.11% in HSC4 (Figure 1).

CD44v3 expression

CD44v3 expression increased in HSC2 from 2.73% to 21.5%. In Sa3, it increased from 0.11% to 1.12%. In HSC4, it increased from 0.76% to 3.83%. In contrast, in HSC3, it decreased from 5.09% to 1.1%. In HO-1-u-1, it decreased from 1.50% to 1.07%, which was not a significant change (Figure 2).

Figure 1: CD44s expression. Five cell lines were subjected to FACS to analyze CD44s. a) The left and right panels show pre-irradiation
Cancer Stem Cell Marker CD44v9

and post-irradiation data, respectively. Data for HO-1-u-1, Sa3, HSC2, HSC3, and HSC4 are shown. b) The graphs show the number of CD44v9-positive cells.

**Figure 2**: CD44v3 expression. Five cell lines were subjected to FACS to analyze CD44v3. a) The left and right panels show pre-irradiation and post-irradiation data, respectively. b) The graphs show the number of CD44v3-positive cells.

**CD44v6 expression**

CD44v6 expression increased in HSC2 from 2.80% to 24.3%. In HSC3, it decreased from 3.16% to 1.03%. In other cell lines, CD44v6 was scarcely expressed, but expression showed a slight increase (Figure 3).

**CD44v9 expression increased in all cell lines**

CD44v9 expression increased from 3.07% to 24.2% in HO-1-u-1, from 1.19% to 26.9% in Sa3, from 1.96% to 17.9% in HSC2, from 1.57% to 47.4% in HSC3, and from 0.59% to 8.14% in HSC4, representing an increase in expression in all cell lines. (p < 0.001) (Figure 4)
CD44v9 expression. Five cell lines were subjected to FACS to analyze CD44v9. a) The left and right panels show pre-irradiation and post-irradiation data, respectively. b) The graphs show the number of CD44v9-positive cells.

Colony Formation Assay

HO-1-u-1, Sa3, HSC2, HSC3, and HSC4 were able to form a large-size colony after irradiation (Figure 5a). Further, they formed significantly more colonies after irradiation (p < 0.01) (Figure 5b).

After irradiation, the number of CD44v9 increased, whereas that of CD44s decreased. In addition, the number of CD44v3 and CD44v6 increased in some cell lines, whereas decreased in other cell lines. After irradiation, the colony-forming ability was enhanced, and the number of cancer stem cell-like cells appeared to have increased. These results indicated that irradiation induced changes in CD44 variants, among which CD44v9 was suggested to be a cancer stem cell marker.

Discussion

CD44 was originally reported as an adhesion molecule expressed in lymphocytes. Recently, there have been many reports on the association of CD44 expression with metastasis. Free cancer cells may circulate in the body via blood vessels and lymphatic vessels using the same mechanism as leukocytes. CD44 functions as a receptor for molecules such as hyaluronic acid, and it has become clear that it can also bind to actin filaments via the ERM protein family. CD44v9 binds to xCT, which is a light-chain subunit of system xc−, a transporter that takes cystine [material of glutathione (GSH)] into cells. The binding by which the CD98 heavy chain becomes a chaperone molecule promotes the formation of reduced GSH, which is an antioxidant, by increasing the stability of xCT at the cell membrane. GSH functions as a scavenger of reactive oxygen species in cancer stem cells, thereby enhancing the resistance of such cells to oxidative stress.

A tumor was originally thought to be a homogeneous population of cells, but it is, in fact, a heterogeneous aggregate of populations. More than 20 years have passed since cancer stem cells were identified. It was originally claimed that cancer stem cells are enriched in the SP cell group, but some non-SP groups also have tumorigenic potential. It was also claimed that CD133 is an absolute marker of glioblastoma, but tumor formation is also possible in CD133− cells. Thus, it is impossible to identify cancer stem cells with a single marker alone; this is also true for CD44 in head and neck cancer. Our experiment showed that cancer stem cells were able to form a number of colonies after irradiation even in the three-dimensional culture system (Figure 5). The increased colony-forming ability in the serum-free semisolid medium indicates the proliferation of cancer stem cells.

In this study, we irradiated cell lines to utilize the properties of cancer stem cells in an attempt to investigate the variants of CD44. The finding we observed was that the expression of CD44s decreased and that the expression of CD44v9 increased upon irradiation (Table 1). Considering that cancer stem cells were enriched by irradiation, it can be said that CD44v9 is one of the stem cell markers for cancer. In addition, the decrease in the expression of CD44s is consistent with a report stating that cancer expressing a lower level of CD44s is more malignant. A report has also demonstrated that CD44v9 plays an important role as a cancer stem cell. Against this background, further analyses of CD44v9 are essential.

Table 1: Fluctuations in the expression of CD44 in various cell lines.

<table>
<thead>
<tr>
<th></th>
<th>HO-1-u-1</th>
<th>Sa3</th>
<th>HSC2</th>
<th>HSC3</th>
<th>HSC4</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD44s</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>CD44v3</td>
<td>→</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>CD44v6</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>CD44v9</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
</tbody>
</table>

CD44s showed decreased expression, while CD44v9 showed increased expression.
Conclusion

We irradiated cell lines and examined variants of CD44. In all cell lines, CD44s expression decreased and CD44v9 expression increased. On the other hand, expression of CD44v3 and CD44v6 were scattering by cell line. Given the importance of CD44v9 and the suggestion that it is one of the cancer stem cell markers, it requires further investigations. Cancer stem cells can be eradicated by establishing a therapy that targets CD44v9, which may lead to the suppression of recurrence and metastasis.

Financials: This work was supported in part by JSPS KAKENHI Grant Numbers 24590472 (to Y. Omori) and 25861525 (to Y. Kawasaki)

Disclosure: No conflicts of interest.

References


Cancer Stem Cell Marker CD44v9